Springfield Clinic’s physicians have conducted clinical trials for over 50 years across numerous medical specialties. To date, the Clinical Research Department has conducted more than 400 clinical trials and continues research activities today. Search the table below to review our current clinical trials, investigators and medical conditions under study.

Please contact us if you have additional questions about Springfield Clinic’s Clinical Research Department or current clinical trial activities.

Condition Principal Investigator Description
Cancer Chaitanya Mamillapalli, MD A computational model to predict response to neoadjuvant therapy in breast cancer
Cancer Preet Singh, MD (and Oncology Department) Members of Heartland NCORP Cancer Research
C-difficile Steven O'Marro, MD A Phase 3 study of SER109 (Ecobiotic Drug) to reduce recurrence of C-diff infection in adults who have received antibiotic treatment for recurrent C-diff infection.
Chronic Cough Renu Govindaiah, MD Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough
Diabetic Retinopathy Ramanath Bhandari, MD Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Diabetic Retinopathy (Enrollment Closed)
Diabetic Macular Edema Ramanath Bhandari, MD Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of DME
Healthcare Machine Learning Chaitanya Mamillapalli, MD Development and evaluation of a machine learning algorithm for prediction of clinical diagnosis
Kidney Transplant Brad West, MD APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
Lung Cancer Screening Jessica Moja, MD Nano-Chip Diagnostic Development for Lung Cancer Screenings
Metastatic Prostate Cancer David Lieber, MD Study of Enzalutamide plus Androgen Deprivation Therapy in men with Metastatic Hormone Sensitive Prostate Cancer (Enrollment Closed)
Neovascular Age-Related Macular Degeneration Ramanath Bhandari, MD A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
Plaque Psoriasis Vivianne Beyer, MD Phase 3 Study of TYK2 inhibitor (oral) Compared to Otezla in adults with mod-severe Plaque Psoriasis
Psoriatic Arthritis Robert Trapp, MD Comparison of risankizumab to placebo in subjects with active Psoriatic Arthritis with inadequate response or intolerance to biologic therapies
Psoriatic Arthritis Robert Trapp, MD Comparison of risankizumab to placebo in subjects with active Psoriatic Arthritis with inadequate response or intolerance to Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Prostate Cancer David Lieber, MD Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Prostate Cancer David Lieber, MD Study comparing the occurrence of Major Adverse Cardiovascular Events in patients receiving Firmagon or Lupron for Prostate Cancer
Rheumatoid Arthritis Robert Trapp, MD Long-term safety study of patients with RA and cardiovascular risk receiving Xeljanz or Humira (along with Methotrexate)(Enrollment Closed)
Rheumatoid Arthritis Robert Trapp, MD Phase 3 study of ABT-494 (JAK inhibitor) for patients with Mod-Severe RA who are on stable doses of DMARD's and have had inadequate response or intolerance to Biologic DMARD's (Enrollment Closed)
Rheumatoid Arthritis Robert Trapp, MD Long-term open-label follow up of GLPG0634 in patients with Rheumatoid Arthritis (Enrollment closed)
Rheumatoid Arthritis Robert Trapp, MD Oral Filgotinib given alone or in combination with Methotrexate in patients with moderate to severe active Rheumatoid Arthritis who are naive to Methotrexate (Enrollment Closed)
Rheumatoid Arthritis Robert Trapp, MD A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
Rheumatoid Arthritis Robert Trapp, MD Phase 3 study of ABT-494 (JAK inhibitor) for patients with Mod-Severe RA who are on stable doses of DMARD's and have had inadequate response (Enrollment Closed)